News & Publications

News

01 December 2023

Cerecin forges strategic partnership with A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders

19 September 2023

Cerecin strengthens position in neurometabolism with addition to pipeline

30 August 2023

Cerecin to Present New Infantile Spasms Data at the 35th Interna1onal Epilepsy Congress, Dublin 2023

30 June 2023

Clinical Trial Data of Novel Metabolic Mechanism in Migraine: CER-0001, a Ketogenic Investigational Agent

07 December 2022

Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile Spasms

25 November 2022

Poster presentation on the Metabolic Mechanism in Migraine: Tricaprilin, a Ketogenic Agent

17 November 2022

Cerecin appoints Mr. Brian Young-Hoon Kim as new Head of Investor Relations

03 November 2022

Cerecin Announces Abstract on New Infantile Spasms Data Accepted for Oral Presentation at the International League Against Epilepsy EME Congress 2022

31 October 2022

Results of Pilot Study of CER-0001 in Migraine support advancement into a pivotal global Phase 2/3 study

10 October 2022

Cerecin appoints Dr. Marc Cantillon as Chief Medical Officer

28 September 2022

Cerecin closes Series IIB financing to advance CER-0001 clinical programs and build pipeline in neuro-metabolism drug development

14 December 2021

Cerecin Announces Appointment of Milan Vinnola as General Counsel

09 November 2021

Cerecin Enrolls First Patient in a Pilot Clinical Trial of Tricaprilin in the Treatment of Infantile Spasms

19 October 2021

Cerecin raises $40 Million Series II and IIA financing to support its programs in neurological disorders

04 February 2021

Julie Liu Joins Cerecin From Pfizer as New Vice President of R&D and Chemicals, Manufacturing and Controls

17 December 2020

Cerecin Enrolls First Patient in a Phase 2 Pilot Clinical Trial of Tricaprilin for Migraine Prevention (the Relief Study)

04 November 2020

Cerecin Announces Presentations of Tricaprilin Data at CTAD 2020

29 October 2020

Cerecin Announces Orphan Drug Designation from U.S. FDA for Tricaprilin in the Treatment of Infantile Spasms

08 October 2020

U.S. FDA Grants Rare Pediatric Disease Designation to Cerecin’s Investigational Drug Tricaprilin for the Treatment of Infantile Spasms

30 July 2020

Cerecin Presents New Data on Tricaprilin at Alzheimer's Association International Conference 2020

29 July 2020

Lilian Chow joins Cerecin as Vice President of Clinical Operations and Regulatory Affairs

07 January 2019

Cerecin appoints Dr. Xiaoping Cao as Head of CMC

11 December 2018

Cerecin Sponsors and Presents at Alzheimer's Disease Therapeutics: Alternatives to Amyloid Symposium

24 October 2018

Cerecin appoints veteran Singaporean Pharmaceutical Executive, Cheryl Tan, as Head of Commercial Strategy

16 October 2018

Cerecin appoints two new members to its Scientific Advisory Board following announcement of new Singapore headquarters

04 October 2018

Accera closes new investment led by Asia's leading agribusiness group, Wilmar, and rebrands as Cerecin

12 Septemeber 2018

Dr. Charles Stacey, Cerecin's President and CEO is appointed to the Board of Governors of the Accreditation Council for Medical Affairs (ACMA)

12 July 2017

Cerecin Enters into a Strategic Partnership and Exclusive Licensing Agreement with DuChemBio for Cerecin's Technology in Korea

In The Media

May 27, 2021

Interview: Cerecin’s company progress and expansion into migraine and infantile spasms

February 1, 2019

Interview: AD is the largest unmet clinical need

October 24, 2018

Interview: Brains and medicine

May 5, 2016

Nestlé Wants to Sell You Both Sugary Snacks and Diabetes Pills

July 2, 2015

Accera Hoping for an Alzheimer’s Breakthrough

June 24, 2015

Accera Pivots From Medical Foods to Potential Drug for Alzheimer’s

Publications

Application of FibroScan for hepatic safety monitoring in early clinical studies

Sabina Paglialunga, PhD, Terry O’Reilly, MD CPI, Samuel Henderson, PhD, Bruce H Morimoto, PhD, Lilian Chow, MRDM, Nor Rahimah binte Ramli, Lars Nelleman, MD, Judith Walker, MD 2021 ACCP Virtual Annual Meeting

Administering tricaprilin after a meal optimises bioavailability and minimises adverse events

Judith Anne Walker, MD; Lars Nelleman,MD; Lilian Chow, MRDM; Bruce Morimoto, PhD Clinical Trials on Alzheimer’s Disease 2020

Tricaprilin shows similar PK, safety and tolerability in Caucasians and Chinese

Bruce H. Morimoto, PhD; Lilian Chow, MRDM; Lars Nelleman,MD; Judith Anne Walker, MD Clinical Trials on Alzheimer’s Disease 2020

An evidence-based risk-mitigation approach to study design in APOE4(-) mild to moderate AD

Judith Anne Walker, MD; Lars Nelleman,MD; Bruce H Morimoto, PhD; Lilian Chow, MRDM Clinical Trials on Alzheimer’s Disease 2020

Novel formulation AC-SD-03 of tricaprilin leads to excellent PK and safety in doses up to 30g BID

Lilian Chow, MRDM; Lars Nelleman, MD; Bruce H. Morimoto, PhD; Judith Anne Walker, MD Clinical Trials on Alzheimer’s Disease 2020

Development of tricaprilin, a ketogenic drug for Alzheimer's disease

Judith Anne Walker, MD; Lars Nelleman,MD; Lilian Chow, MRDM; Samuel T Henderson, PhD Alzheimer's Association International Conference 2020

The rat as a model for CER-0001 formulation development

Samuel T Henderson, PhD, Ameet Ambarkhane PhD, Bruce Morimoto, PhD, and Judith Walker, MD Alzheimer's Association International Conference 2020

A Review of Ketogenic Therapies for Alzheimer’s Disease

S. Henderson Metabolic Health Summit 2019

Events

25-28

January

2024

Global Metabolic Summit

1-5

December

2023

American Epilepsy Society 2023

November

2023

Asian Health and Life Sciences Innovation and Cooperation Summit, Presentation by Charles Stacey

November

2023

Society for Neuroscience (SfN) Singapore. Sponsored by Cerecin

24-27

October

2023

Clinical Trials on Alzheimer’s Disease (CTAD), Boston MA

12-13

October

2023

Biocon Advanced Cell and Gene Therapy Conference 2023, Singapore. Keynote by Charles Stacey

5-8

October

2023

BIO 2023, Boston MA

September

2023

7th Annual Cell and Gene Therapy World Asia Conference, Singapore. Keynote by Charles Stacey

2-6

September

2023

35th International Epilepsy Congress in Dublin, Ireland. Presentation of Data by Marc Cantillon

16-20

July

2023

Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam

17-26

April

2023

Asia Bio Partnering Forum in Singapore

January

2023

Neuroscience Innovation Forum in San Francisco. Panel discussion on Rare and Orphan Diseases by Charles Stacey

9–12

November

2021

Clinical Trials on Alzheimer's Disease conference (CTAD)

19–23

October

2021

7th Global Symposium on medical ketogenic dietary therapies

8 – 12

September

2021

IHC 2021 – International Headache Congress – IHS and EHF joint congress 2021

25–27

August

2021

ISPE Singapore Conference & Exhibition 2021

25–26

August

2021

Annual Biomarkers for Alzheimer’s Disease Summit

26-30

July

2021

Alzheimer's Association International Conference (AAIC)

13-15

July

2021

Healthy Ageing APAC Summit

7–8

July

2021

DIA-CoRE Singapore Annual Meeting 2021

27-1

June-July

2021

DIA 2021 Global Annual Meeting

10-13

June

2021

13th Asian and Oceanian Epilepsy Congress (AOEC)

28-30

April

2021

4th Annual Neuroscience Innovation Forum

25-28

April

2021

The World Orphan Drug Congress USA 2021

17–21

April

2021

American Academy of Neurology Annual Meeting (AAN Annual Meeting)

17–25

March

2021

Online Migraine World Summit 2021

8-10

October

2020

International Congress of the Asian Society against Dementia, ASAD 2020 Virtual Meeting

13-14

October

2020

Precision in Clinical Trials Virtual Summit

October

2020

Solebury Trout Virtual Private Company Showcase

11-13

November

2020

TIDES Europe: Oligonucleotide & Peptide Therapeutics

8-10

December

2020

News & Publications

News & Publications

News

Cerecin forges strategic partnership with A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders

Cerecin strengthens position in neurometabolism with addition to pipeline

Cerecin to Present New Infantile Spasms Data at the 35th Interna1onal Epilepsy Congress, Dublin 2023

Clinical Trial Data of Novel Metabolic Mechanism in Migraine: CER-0001, a Ketogenic Investigational Agent

Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile Spasms

Poster presentation on the Metabolic Mechanism in Migraine: Tricaprilin, a Ketogenic Agent

Cerecin appoints Mr. Brian Young-Hoon Kim as new Head of Investor Relations

Cerecin Announces Abstract on New Infantile Spasms Data Accepted for Oral Presentation at the International League Against Epilepsy EME Congress 2022

Results of Pilot Study of CER-0001 in Migraine support advancement into a pivotal global Phase 2/3 study

Cerecin appoints Dr. Marc Cantillon as Chief Medical Officer

Cerecin closes Series IIB financing to advance CER-0001 clinical programs and build pipeline in neuro-metabolism drug development

Cerecin Announces Appointment of Milan Vinnola as General Counsel

Cerecin Enrolls First Patient in a Pilot Clinical Trial of Tricaprilin in the Treatment of Infantile Spasms

Cerecin raises $40 Million Series II and IIA financing to support its programs in neurological disorders

Julie Liu Joins Cerecin From Pfizer as New Vice President of R&D and Chemicals, Manufacturing and Controls

Cerecin Enrolls First Patient in a Phase 2 Pilot Clinical Trial of Tricaprilin for Migraine Prevention (the Relief Study)

Cerecin Announces Presentations of Tricaprilin Data at CTAD 2020

Cerecin Announces Orphan Drug Designation from U.S. FDA for Tricaprilin in the Treatment of Infantile Spasms

U.S. FDA Grants Rare Pediatric Disease Designation to Cerecin’s Investigational Drug Tricaprilin for the Treatment of Infantile Spasms

Cerecin Presents New Data on Tricaprilin at Alzheimer's Association International Conference 2020

Cerecin Sponsors Alzheimer’s Disease Association (ADA) Walk2Remember 2020

Cerecin appoints biotech veteran Joseph S. Zakrzewski as its new Chairman

Bruce Morimoto joins Cerecin as Vice President of Drug Development

Lilian Chow joins Cerecin as Vice President of Clinical Operations and Regulatory Affairs

Cerecin appoints Dr. Xiaoping Cao as Head of CMC

Cerecin Sponsors and Presents at Alzheimer's Disease Therapeutics: Alternatives to Amyloid Symposium

Cerecin appoints veteran Singaporean Pharmaceutical Executive, Cheryl Tan, as Head of Commercial Strategy

Cerecin appoints two new members to its Scientific Advisory Board following announcement of new Singapore headquarters

Accera closes new investment led by Asia's leading agribusiness group, Wilmar, and rebrands as Cerecin

Dr. Charles Stacey, Cerecin's President and CEO is appointed to the Board of Governors of the Accreditation Council for Medical Affairs (ACMA)

Cerecin Enters into a Strategic Partnership and Exclusive Licensing Agreement with DuChemBio for Cerecin's Technology in Korea

In The Media

Interview: Cerecin’s company progress and expansion into migraine and infantile spasms

Interview: AD is the largest unmet clinical need

Interview: Brains and medicine

Nestlé Wants to Sell You Both Sugary Snacks and Diabetes Pills

Accera Hoping for an Alzheimer’s Breakthrough

Accera Pivots From Medical Foods to Potential Drug for Alzheimer’s

Publications

Application of FibroScan for hepatic safety monitoring in early clinical studies

Administering tricaprilin after a meal optimises bioavailability and minimises adverse events

Tricaprilin shows similar PK, safety and tolerability in Caucasians and Chinese

An evidence-based risk-mitigation approach to study design in APOE4(-) mild to moderate AD

Novel formulation AC-SD-03 of tricaprilin leads to excellent PK and safety in doses up to 30g BID

Development of tricaprilin, a ketogenic drug for Alzheimer's disease

The rat as a model for CER-0001 formulation development

A Review of Ketogenic Therapies for Alzheimer’s Disease

Events

Global Metabolic Summit

American Epilepsy Society 2023

Asian Health and Life Sciences Innovation and Cooperation Summit, Presentation by Charles Stacey

Society for Neuroscience (SfN) Singapore. Sponsored by Cerecin

Clinical Trials on Alzheimer’s Disease (CTAD), Boston MA

Biocon Advanced Cell and Gene Therapy Conference 2023, Singapore. Keynote by Charles Stacey

BIO 2023, Boston MA

7th Annual Cell and Gene Therapy World Asia Conference, Singapore. Keynote by Charles Stacey

35th International Epilepsy Congress in Dublin, Ireland. Presentation of Data by Marc Cantillon

Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam

Asia Bio Partnering Forum in Singapore

Neuroscience Innovation Forum in San Francisco. Panel discussion on Rare and Orphan Diseases by Charles Stacey

Clinical Trials on Alzheimer's Disease conference (CTAD)

7th Global Symposium on medical ketogenic dietary therapies

IHC 2021 – International Headache Congress – IHS and EHF joint congress 2021

ISPE Singapore Conference & Exhibition 2021

Annual Biomarkers for Alzheimer’s Disease Summit

Alzheimer's Association International Conference (AAIC)

Healthy Ageing APAC Summit

DIA-CoRE Singapore Annual Meeting 2021

DIA 2021 Global Annual Meeting

13th Asian and Oceanian Epilepsy Congress (AOEC)

4th Annual Neuroscience Innovation Forum

The World Orphan Drug Congress USA 2021

American Academy of Neurology Annual Meeting (AAN Annual Meeting)

Online Migraine World Summit 2021

International Congress of the Asian Society against Dementia, ASAD 2020 Virtual Meeting

Precision in Clinical Trials Virtual Summit

Solebury Trout Virtual Private Company Showcase